| Ytd | -28.77% | |
| 1y | -13.11% |
| Open | 4.07 | Prev Close | 4.07 | Low | 4.05 | High | 4.20 | Mkt Cap | 112.59M |
| Vol | 551.39K | Avg Vol | 839.30K | EPS | -1.72 | P/E | N/A | Forward P/E | -3.31 |
| Beta | 2.29 | Short Ratio | 0.74 | Inst. Own | 38.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 5.03 | 200-d Avg | 6.28 | 1yr Est | 5.50 |
UNCY News
New York, New York--(Newsfile Corp. - October 10, 2026) - WHY: Rosen Law Firm, a global investor rig
New York, New York--(Newsfile Corp. - October 9, 2026) - WHY: Rosen Law Firm, a global investor righ
New York, New York--(Newsfile Corp. - October 9, 2026) - Kaplan Fox & Kilsheimer LLP announces that
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remin
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L
New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud
A securities class action alleges Unicycive Therapeutics told investors its third-party manufacturer
New York, New York--(Newsfile Corp. - October 8, 2026) - The law firm of Kirby McInerney LLP reminds
New York, New York--(Newsfile Corp. - October 7, 2026) - WHY: Rosen Law Firm, a global investor righ
LOS ANGELES, Oct. 7, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suf
A securities class action alleges Unicycive Therapeutics never inspected or audited its third-party
New York, New York--(Newsfile Corp. - October 6, 2026) - WHY: Rosen Law Firm, a global investor righ
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
A securities class action alleges Unicycive Therapeutics spent six months telling shareholders its O
ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Holzer and Holzer, LLC reminds investors of the deadline
New York, New York--(Newsfile Corp. - October 5, 2026) - WHY: Rosen Law Firm, a global investor righ
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors o
A securities class action alleges Unicycive Therapeutics told shareholders its oxylanthanum carbonat
New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud
San Diego, California--(Newsfile Corp. - October 5, 2026) - Shareholder rights law firm Robbins LLP
New York, New York--(Newsfile Corp. - October 5, 2026) - Kaplan Fox & Kilsheimer LLP announces that
New York, New York--(Newsfile Corp. - October 4, 2026) - WHY: Rosen Law Firm, a global investor righ
New York, New York--(Newsfile Corp. - October 3, 2026) - WHY: Rosen Law Firm, a global investor righ
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:U
The Company anticipates United States Food and Drug Administration (FDA) acceptance of the NDA with
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowe
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.06) per share which beat the a
Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative
Noble Capital Markets analyst Robert LeBoyer maintains Unicycive Therapeutics (NASDAQ:UNCY) with
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:U
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#
B. Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ:UNCY) with a
US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%.
Unicycive Therapeutics ($UNCY) stock crashes over 46% as FDA rejects kidney disease drug NDA again o
US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up
Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market s
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therap
https://www.sec.gov/Archives/edgar/data/1766140/000121390026065819/ea0291789-s3_unicycive.htm
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowe
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.54) per share which missed the